Fabry Disease in 21 Major Markets – 2018-2028 – ResearchAndMarkets.com

Epidemiology Series: Fabry Disease Forecast In 21 Major Markets
report has been added to ResearchAndMarkets.com’s

This report provides the current prevalent population for Fabry Disease
across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK,
Poland, Netherlands, Austria, Portugal, Russia, Turkey, Japan, China,
South Korea, India, Australia, Brazil, Mexico, Argentina) split by
gender and 5-year age cohort. Along with the current prevalence, the
report also contains a disease overview of the risk factors, disease
diagnosis and prognosis along with specific variations by geography and

Providing a value-added level of insight from the analysis team, several
of the main symptoms and co-morbidities of Fabry disease have been
quantified and presented alongside the overall prevalence figures. These
sub-populations within the main disease are also included at a country
level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

  • Angiokeratoma
  • Cornea verticillata (corneal whorling)
  • Hearing loss
  • Tinnitus
  • Proteinuria
  • Cardiac hypertrophy & arrhythmias
  • Sweating dysfunction

Reasons to buy

  • Able to quantify patient populations in global Fabry disease market to
    target the development of future products, pricing strategies and
    launch plans.
  • Gain further insight into the prevalence of the subdivided types of
    Fabry disease and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study
    sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid
    conditions on Fabry disease prevalent population.
  • Identify sub-populations within Fabry disease which require treatment.
  • Gain an understanding of the specific markets that have the largest
    number of Fabry disease patients.

Key Topics Covered:

  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Comorbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Prevalence for Fabry Disease
  • Features of Fabry Disease Patients
  • Abbreviations Used in the Report
  • Online Epidemiology Databases
  • Online Pharmaceutical Pricing Database

For more information about this report visit https://www.researchandmarkets.com/research/6xg6r7/fabry_disease_in?w=4


Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Endocrine
and Metabolic Disorders Drugs